Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform.
Funding Details
Proceeds will support R-Nanoablation’s pipeline, including devices for tumors, atrial fibrillation, and chronic encephalopathy. The company plans to leverage its ultra-high voltage, ultra-short nsPEF technology, which offers tissue selectivity and rapid energy release, positioning it as a next-gen ablation solution.
Company Profile
Founded in 2014, R-Nanoablation has multiple products in development, with some holding fast-track status in China. Its nsPEF platform is designed to improve efficacy and safety in minimally invasive treatments, targeting unmet needs in oncology and cardiology.
Strategic Outlook
The Series B+ funding will help R-Nanoablation scale clinical trials and prepare for regulatory submissions. The company aims to establish its nsPEF technology as a standard in ablation therapies, with plans to expand globally.-Fineline Info & Tech
